TERT and neoplasm: Based on the finding that TERT leads to different outcomes in IDH1- and IDH2-mutant tumours, we propose that genetic testing for IDH1, IDH2, and TERT promoter mutations in the context of other clinical factors, could be useful in patient stratification.